Trump 2.0 presents opportunities, threats

Nothing has changed in Washington, but two months ahead of inauguration day, it already feels as if everything is different. Biopharma leaders believe there is an urgent need to seize the opportunities and head off threats posed by the incoming administration.

A consensus has emerged among pharmaceutical and biotech CEOs who are trying to plot a course through the transition and into the new Congress and administration. They are looking for areas of common ground with President-elect Donald Trump and his nominees for critical positions, hoping to steer clear of conflict, and sketching out red lines that would lead them to go on the offensive. ...